 CAMBRIDGE, Mass., Nov. 09, 2020 GLOBE NEWSWIRE -- Praxis Precision Medicines, Inc. NASDAQ: PRAX, a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. Food and Drug Administration FDA on the Investigational New Drug IND submission for PRAX-114 for the treatment of major depressive disorder MDD. 